Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

NCT07147257 is registered in ClinicalTrials.gov with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07147257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07147257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions
Lead sponsor
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 12, 2025
Completion date
May 29, 2025
Enrollment
238 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants